课题基金 / 基金详情

CONTROL OF TYPE II CELL FUNCTION BY PNEUMOCYSTIS CARINII

CONTROL OF TYPE II CELL FUNCTION BY PNEUMOCYSTIS CARINII
卡氏肺囊虫对 II 型细胞功能的控制
批准号:
2223104
负责人:
WARD R RICE
金额:
$21.25万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-03-04 至 1994-12-31

项目摘要

项目成果

WARD R RICE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Significant lung dysfunction results from Pneumocystis carinii pneumonia in immunocompromised patients. Despite the magnitude of this problem, little is known of the mechanisms by which Pneumocystis carinii produces this lung dysfunction. The proposed study will test the hypothesis that Pneumocystis carinii interacts with alveolar Type II cells which synthesize and secrete surfactant-associated phospholipids and proteins to produce the lung dysfunction observed in Pneumocystis carinii pneumonia. Systematic studies will be undertaken to identify developmental stages and specific components of Pneumocystis carinii responsible for inhibition of Type II cell function. A biochemical characterization of the inhibitory components will be undertaken and the mechanism by which Pneumocystis carinii influences Type II cell production of phospholipids and surfactant-associated proteins will be determined. Polyclonal and monoclonal antibodies directed against components of Pneumocystis carinii will be utilized to define specific epitopes involved in regulation of Type II cell function. These in vitro studies will then be correlated with an in vivo model of Pneumocystis carinii pneumonia in the rat, to determine whether in vitro observations with isolated Type II cells are relevant to the intact animal. The overall objective of these studies is to determine cellular mechanisms involved in production of lung dysfunction during Pneumocystis carinii pneumonia. The data obtained will be invaluable in designing rational therapeutic approaches for immunocompromised patients with Pneumocystis carinii pneumonia and will further our understanding of factors regulating surfactant production by the alveolar Type II cell.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.
Ro 11-8958 和其他二氢叶酸还原酶抑制剂与磺胺甲恶唑和氨苯砜的协同组合用于治疗实验性肺囊虫病。
DOI: 10.1128/aac.37.7.1436
发表时间: 1993
期刊: Antimicrobial agents and chemotherapy
影响因子: 4.9
作者: [Walzer,PD, Foy,J, Steele,P, White,M]
通讯作者: White,M
Guanylhydrazones in therapy of Pneumocystis carinii pneumonia in immunosuppressed rats.
脒基腙治疗免疫抑制大鼠卡氏肺孢子虫肺炎。
DOI: 10.1128/aac.38.11.2572
发表时间: 1994
期刊: Antimicrobial agents and chemotherapy
影响因子: 4.9
作者: [Walzer,PD, Foy,J, Runck,J, Steele,P, White,M, Klein,RS, Otter,BA, Sundberg,RJ]
通讯作者: Sundberg,RJ
Fractionation of Pneumocystis carinii developmental stages by counterflow centrifugal elutriation and sequential filtrations.
通过逆流离心淘洗和顺序过滤对卡氏肺囊虫发育阶段进行分级。
DOI: 10.1007/bf00932616
发表时间: 1994
期刊: Parasitology research
影响因子: 2
作者: [DeStefano,JA, Foy,JM, Sullivan,DW, Dawes,SM, Cushion,MT, Babcock,GF, Sleight,RG, vanHalbeek,H, Walzer,PD]
通讯作者: Walzer,PD
CORE--CELL CULTURE
GM-CSF AND RECEPTORS IN TYPE II CELL PROLIFERATION/DIFFERENTIATION/FUNCTION
CORE--CELL CULTURE
GM-CSF AND RECEPTORS IN TYPE II CELL PROLIFERATION/DIFFERENTIATION/FUNCTION
海外基金